A government-sponsored clinical trial testing a COVID-19 antibody treatment made by the Eli Lilly (LLY) has been paused because of a “potential safety concern,” according to The New York Times’ Katherine J. Wu and Katie Thomas, citing emails from government officials and confirmed by the company. Molly McCully, a spokeswoman for Eli Lilly, confirmed the pause, stating: “Safety is of the upmost importance to Lilly. Lilly is supportive of the decision by the independent D.S.M.B. to cautiously ensure the safety of the patients participating in this study.” The news comes after Johnson & Johnson (JNJ) announced yesterday the pause of its coronavirus vaccine trial and a month after AstraZeneca’s (AZN) vaccine trial was halted over concerns about two participants who had fallen ill, the report noted. Source: https://www.nytimes.com/live/2020/10/13/world/coronavirus-covid/eli-lilly-antibody-trial-is-paused-because-of-potential-safety-concerns?partner=bloomberg

The study of Johnson & Johnson’s Covid-19 vaccine has been paused due to an unexplained illness in a study participant. CNBC’s Jim Cramer and David Faber discuss the development and whether it affects Johnson & Johnson’s stocks.

Source: https://www.youtube.com/watch?v=1z6yOw55MAY

finviz dynamic chart for  jnj finviz dynamic chart for  lly finviz dynamic chart for  azn